Boehringer Ingelheim GmbH has exercised an option to acquire Austria-based ViraTherapeutics GmbH which is developing oncolytic virus vaccines to treat cancer. The transaction has been valued at €210 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
